IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
This study has been terminated.
(Higher hemorrhage rates of Abciximab in ABESST II trial)
Sponsor:
University of Zurich
Collaborators:
Schweizerische Herzstiftung
Eli Lilly and Company
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00126139
First received: July 29, 2005
Last updated: May 1, 2007
Last verified: May 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the present prospective, randomized, double-blind, double dummy controlled multicenter pilot study is to investigate whether abciximab, compared with aspirin, is able to reduce the rate of recurrent ischemic strokes before and during carotid endarterectomy [CEA] (primary endpoints); and the degree of carotid stenosis, number of microembolic signal (MES) counts, number of ischemic infarcts at diffusion weighted imaging (DWI) and amount of intraluminal thrombus at pathological examination (secondary endpoints) in patients with ischemic stroke due to a >50% carotid stenosis who will undergo CEA.
| Condition | Intervention | Phase |
|---|---|---|
| Stroke Stenosis | Drug: Abciximab | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Abciximab Versus Aspirin for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic >50% Carotid Stenosis: A Pilot Study (ASTERICS) |
Resource links provided by NLM:
Further study details as provided by University of Zurich:
Primary Outcome Measures:
- Whether abciximab compared with aspirin reduces the rate of recurrent ischemic strokes in territory of symptomatic carotid artery during administration of study drug, preoperative period or carotid endarterectomy
Secondary Outcome Measures:
- Reduction of the degree of carotid stenosis at ultrasound studies performed 48-72 h after compared to 24 h prior to iv administration of the study agents.
- Reduction of MES counts measured 48-72 h after compared to 24 h prior to the administration of the iv study drugs.
- Difference of number of acute ischemic infarct on DWI assessed 48-72 h after compared to 24 h prior to the administration of the iv study drugs.
- Symptomatic ICH and asymptomatic hemorrhagic transformation occurring during or within 48-72 h after the administration of the iv study drugs.
- Size of plaque/intraplaque thrombus and intraplaque hemorrhage will be assessed at pathological examination of endarterectomy specimen after CEA.
- Clinical outcome at 90 days will be assessed using the NIHSS and the mRS.
| Estimated Enrollment: | 100 |
| Study Start Date: | April 2004 |
| Study Completion Date: | May 2005 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age at least 18 years.
- Presence of symptoms of an ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) scale of one up to 20 or due to an ipsilateral atherosclerotic >50% stenosis of the extracranial internal carotid artery (ICA) as shown by ultrasonography.
- Latency between the onset of stroke symptoms and intended administration of the study drugs is not more than 24 hours.
- Latency between the intended administration of the study drugs and intended carotid endarterectomy is at least three days.
Exclusion Criteria:
- Documented peptic ulcer disease within the preceding 30 days.
- Septicemia or severe localized infection.
- Severe illness (active cancer or significant liver or renal disease) or disability.
- Alcohol or illicit drug abuse.
- Pregnancy.
- Need for chronic anticoagulant therapy (e.g. atrial fibrillation, deep venous thrombosis).
- Need for long-term daily nonsteroidal antiinflammatory drugs.
- Contraindications for platelet therapy such as severe bleeding disorder within the past three months prior to randomization (coagulopathy, platelet disorder including history of heparin-induced thrombopenia, hemorrhage) or significant retinopathy with hemorrhages and exudates.
- Hypersensitivity to abciximab, murine monoclonal antibodies or aspirin.
- Any preexisting intracranial neurological disease such as tumor or multiple sclerosis.
- Intracranial or intraspinal operation or trauma or lumbar puncture within the last 2 months.
- Cardiac lesions likely to cause cardioembolism.
- Suspicion of or established non-atherosclerotic carotid artery disease such as dissection or vasculitis (Takayasu disease, giant cell arteritis, significant collagen vascular disease, systemic necrotizing vasculitis, granulomatous angiitis of the nervous system).
- Participation in another acute stroke trial investigating drugs other than abciximab.
- Treatment for the present stroke with tissue plasminogen activator, urokinase or ancrod.
- ICH, aneurysm, vascular malformation or arteriovenous fistula or sinovenous thrombosis of the brain.
- Brain infarct involving the whole territory of the middle cerebral artery (MCA).
- Stupor or coma.
- Uncontrolled hypertension (systolic pressure >200 mmHg and/or diastolic pressure >110 mmHg).
- No informed consent.
- Contraindication to undergo magnetic resonance (MR) imaging (eg pacemaker).
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00126139
Please refer to this study by its ClinicalTrials.gov identifier: NCT00126139
Locations
| Switzerland | |
| University of Basel, Department of Neurology | |
| Basel, Switzerland, 4031 | |
| University of Bern, Department of Neurology | |
| Bern, Switzerland, 3010 | |
| University of Geneva, Department of Neurology | |
| Geneva, Switzerland, 1211 | |
| University of Lausanne, Department of Neurology | |
| Lausanne, Switzerland, 1011 | |
| University of Zurich, Department of Neurology | |
| Zurich, Switzerland, 8091 | |
Sponsors and Collaborators
University of Zurich
Schweizerische Herzstiftung
Eli Lilly and Company
Investigators
| Study Chair: | Ralf W. Baumgartner, MD | University Hospital of Zurich, Department of Neurology, Switzerland |
More Information
| ClinicalTrials.gov Identifier: | NCT00126139 History of Changes |
| Other Study ID Numbers: |
E-046/2001 |
| Study First Received: | July 29, 2005 |
| Last Updated: | May 1, 2007 |
Keywords provided by University of Zurich:
|
stroke, ischemic stenosis, internal carotid artery Acute ischemic stroke Stenosis of extracranial internal carotid artery |
Additional relevant MeSH terms:
|
Stroke Recurrence Constriction, Pathologic Carotid Stenosis Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Disease Attributes |
Pathologic Processes Pathological Conditions, Anatomical Carotid Artery Diseases Arterial Occlusive Diseases Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments Anticoagulants Platelet Aggregation Inhibitors Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 28, 2017